HUE047263T2 - Staphylococcus aureus antigének stabil immunogén készítményei - Google Patents

Staphylococcus aureus antigének stabil immunogén készítményei

Info

Publication number
HUE047263T2
HUE047263T2 HUE16193095A HUE16193095A HUE047263T2 HU E047263 T2 HUE047263 T2 HU E047263T2 HU E16193095 A HUE16193095 A HU E16193095A HU E16193095 A HUE16193095 A HU E16193095A HU E047263 T2 HUE047263 T2 HU E047263T2
Authority
HU
Hungary
Prior art keywords
staphylococcus aureus
immunogenic compositions
aureus antigens
stable immunogenic
stable
Prior art date
Application number
HUE16193095A
Other languages
English (en)
Hungarian (hu)
Inventor
Lakshmi Khandke
Akihisa Nonoyama
Tamara Shafer Hodge
Sandeep Nema
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUE047263T2 publication Critical patent/HUE047263T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
HUE16193095A 2010-12-22 2011-12-21 Staphylococcus aureus antigének stabil immunogén készítményei HUE047263T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
HUE047263T2 true HUE047263T2 (hu) 2020-04-28

Family

ID=45444677

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16193095A HUE047263T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének stabil immunogén készítményei
HUE11804822A HUE033072T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének immunogén készítményei

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE11804822A HUE033072T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének immunogén készítményei

Country Status (18)

Country Link
US (1) US20130259896A1 (enExample)
EP (2) EP2654784B1 (enExample)
JP (1) JP6097478B2 (enExample)
KR (2) KR101808398B1 (enExample)
CN (1) CN103826656B (enExample)
AU (1) AU2011346535B2 (enExample)
BR (1) BR112013016153A2 (enExample)
CA (1) CA2819120C (enExample)
DK (2) DK3150222T3 (enExample)
ES (2) ES2769425T3 (enExample)
HU (2) HUE047263T2 (enExample)
IL (1) IL226793B (enExample)
MX (1) MX350170B (enExample)
PL (2) PL3150222T3 (enExample)
PT (2) PT2654784T (enExample)
RU (1) RU2570730C2 (enExample)
SI (2) SI2654784T1 (enExample)
WO (1) WO2012085872A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
ES2614807T3 (es) * 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
AU2012266880A1 (en) * 2011-03-16 2013-10-03 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2015082571A1 (en) * 2013-12-04 2015-06-11 Glycovaxyn Ag Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
DK3129001T3 (da) * 2014-04-10 2020-01-20 Asit Biotech S A Hsp-fri fremstilling af allergen
US20200360500A1 (en) * 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
KR102058961B1 (ko) 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU1537699A (en) 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
WO2000012131A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
RU2413520C2 (ru) 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CN1541111A (zh) 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
US7285281B2 (en) 2001-06-07 2007-10-23 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
EP2320233A1 (en) 2001-06-15 2011-05-11 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
KR101541383B1 (ko) * 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
CL2007003209A1 (es) * 2006-11-07 2008-05-09 Acambis Inc Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
SI2445522T1 (sl) * 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa

Also Published As

Publication number Publication date
PT3150222T (pt) 2020-02-03
EP2654784A2 (en) 2013-10-30
EP3150222B1 (en) 2019-11-27
EP2654784B1 (en) 2016-12-07
CN103826656A (zh) 2014-05-28
ES2614815T3 (es) 2017-06-02
CA2819120C (en) 2016-07-05
PL2654784T3 (pl) 2017-08-31
IL226793B (en) 2019-02-28
WO2012085872A2 (en) 2012-06-28
DK3150222T3 (da) 2020-01-27
HK1197370A1 (en) 2015-01-16
JP6097478B2 (ja) 2017-03-15
RU2570730C2 (ru) 2015-12-10
MX350170B (es) 2017-08-28
PL3150222T3 (pl) 2020-05-18
PT2654784T (pt) 2017-02-13
US20130259896A1 (en) 2013-10-03
AU2011346535A1 (en) 2013-06-13
WO2012085872A3 (en) 2012-08-30
ES2769425T3 (es) 2020-06-25
EP3150222A1 (en) 2017-04-05
DK2654784T3 (en) 2017-02-13
KR20150129071A (ko) 2015-11-18
HUE033072T2 (hu) 2017-11-28
SI2654784T1 (sl) 2017-01-31
AU2011346535B2 (en) 2015-09-24
KR20130114210A (ko) 2013-10-16
JP2012136518A (ja) 2012-07-19
CA2819120A1 (en) 2012-06-28
KR101808398B1 (ko) 2017-12-12
MX2013006960A (es) 2013-07-15
BR112013016153A2 (pt) 2017-07-11
RU2013128277A (ru) 2015-01-27
SI3150222T1 (sl) 2020-02-28
CN103826656B (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
IL217084A0 (en) Immunogenic compositions of staphylococcus aureus antigens
IL226793B (en) Stable immunogenic compositions of staphylococcus aureus antigens
ZA202002470B (en) Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
IL231104A0 (en) Helper assemblies of antigens for Staphylococcus aureus
EP2549993A4 (en) ANTIMICROBIAL COMPOSITIONS
ZA201403788B (en) Stable pesticidal compositions
ZA201300073B (en) Compositions comprising optical benefit agents
AP2013006786A0 (en) Pesticidal compositions
AP2013006769A0 (en) Pesticidal compositions
BR112013017664A2 (pt) composições de pó de cacau
GB201015132D0 (en) Vaccine composition
IL238328A0 (en) Stable preparations that include peracetic acid
PL2768936T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
EP2531026A4 (en) ANTIMICROBIAL FORMULATIONS ON POLYSACCHARID BASE
EP2605654A4 (en) ANTIMICROBIAL COMPOSITIONS
PL2407155T3 (pl) Formulacje inekalcytolu
ZA201301908B (en) Immunogenic compositions
GB201013150D0 (en) Antimicrobial compositions
GB201111128D0 (en) Antimicrobial compositions
GB201010944D0 (en) Antimicrobial compositions
GB201003799D0 (en) Antimicrobial compositions
GB201002594D0 (en) Antimicrobial compositions
AU2012900227A0 (en) Compositions of nimorazole
GB201005587D0 (en) Novel formulations